Výsledky vyhledávání - "M. C. Kapetanovic"

POS0255 PREDICTORS OF ANTIBODY RESPONSE TO COVID-19 VACCINE IN RITUXIMAB TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. A SWEDISH NATIONWIDE STUDY (COVID19-REUMA)

Autor: M. Frodlund, K. Chatzidionysiou, A. Södergren, E. Klingberg, M. Hansson, E. Pin, S. Olsson, A. Bengtsson, L. Klareskog, M. C. Kapetanovic

Publikováno v: Annals of the Rheumatic Diseases. 81:368-369

BackgroundIn line with other reports, our group showed that patients treated with rituximab had significant impaired antibody response compared to patients treated with other biologic and targeted and synthetic disease modifying anti-rheumatic drugs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d50a64a0cbfabfc460fb71302cff05ce
https://doi.org/10.1136/annrheumdis-2022-eular.2788

Zobrazit plný text záznamu

OP0262 PREVALENCE AND PREDICTORS OF ACHIEVING SUSTAINED REMISSION IN PSORIATIC ARTHRITIS

Autor: O. Palsson, J. T. Einarsson, J. K. Wallman, T. Love, B. Gudbjornsson, M. C. Kapetanovic

Publikováno v: Annals of the Rheumatic Diseases. 81:173-174

BackgroundIncreased availability and a wide selection of b/tsDMARDs with different mode of action has made long-term remission a realistic treatment goal in psoriatic arthritis.ObjectivesTo estimate the prevalence and possible predictors of sustained

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c79c71fa3f00d4808d63c4fefbcae066
https://doi.org/10.1136/annrheumdis-2022-eular.3724

Zobrazit plný text záznamu

POS0547 THE ADVANTAGE OF TIGHT CONTROL AND TREAT TO TARGET IN NEW-ONSET RA PATIENTS IN DAILY RHEUMATOLOGY PRACTICE: RESULTS FROM A CONTEMPORARY UNIVERSITY CLINIC INCEPTION COHORT

Autor: J. T. Einarsson, K. Friberger Pajalic, C. Bengtsson, E. Mogard, E. Lindqvist, C. Roseman, O. Palsson, J. K. Wallman, T. Olofsson, M. C. Kapetanovic

Publikováno v: Annals of the Rheumatic Diseases. 81:537-538

BackgroundSince 2018, all patients with new-onset rheumatoid arthritis (RA) at the Department of Rheumatology, Skane University Hospital, Lund, Sweden, are offered to participate in a ”tight control” and ”treat to target” (TC+T2T) follow-up s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be561b4ae91ae73b2992f546576db3e1
https://doi.org/10.1136/annrheumdis-2022-eular.2963

Zobrazit plný text záznamu

OP0172 THE IMPACT OF IMMUNOMODULATING TREATMENT ON THE IMMUNOGENICITY OF COVID-19 VACCINES IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES COMPARED TO HEALTHY CONTROLS. A SWEDISH NATIONWIDE STUDY (COVID19-REUMA)

Autor: M. Frodlund, K. Chatzidionysiou, A. Södergren, E. Klingberg, A. Bengtsson, L. Klareskog, M. C. Kapetanovic

Publikováno v: Annals of the Rheumatic Diseases. 81:113-114

BackgroundInitial studies on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases (IRD) reported diminished antibody response in general, and particularly when treated with rituximab or abatacept (1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a41c8b2d725c9f578d4b979905d206d0
https://doi.org/10.1136/annrheumdis-2022-eular.1600

Zobrazit plný text záznamu

OP0058 CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL

Publikováno v: Annals of the Rheumatic Diseases. 81:38.2-40

BackgroundThe optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established.ObjectivesTo compare clinical and radiographic outcomes of active conventional therapy (ACT) with each of three biological therapies with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b8fcab7edd07c88a15264a1ce6955d6
https://doi.org/10.1136/annrheumdis-2022-eular.868

Zobrazit plný text záznamu